---
{"dg-publish":true,"permalink":"/entities/condition/parkinson-s-disease/","tags":["condition","neurodegeneration","movement-disorder","dopamine"]}
---


# Parkinson's Disease

## Overview
Parkinson's Disease (PD) is the second most common neurodegenerative disorder after Alzheimer's Disease. It primarily affects the dopaminergic neurons in the **substantia nigra pars compacta**, leading to motor dysfunction. The pathological hallmark is the presence of **Lewy bodies** containing aggregated **alpha-synuclein** protein.

## Cardinal Motor Symptoms
1. **Tremor**: Resting tremor, typically "pill-rolling"
2. **Rigidity**: Increased muscle tone, "cogwheel" rigidity
3. **Bradykinesia**: Slowness of movement initiation and execution
4. **Postural Instability**: Balance and gait disturbances (late stage)

## Non-Motor Symptoms
- REM sleep behavior disorder (often prodromal)
- Anosmia (loss of smell)
- Constipation and autonomic dysfunction
- Depression and anxiety
- Cognitive impairment progressing to dementia

## Key Mechanisms
1. **Alpha-Synuclein Aggregation**: Misfolded alpha-synuclein forms toxic oligomers and Lewy bodies
2. **Mitochondrial Dysfunction**: Complex I deficiency and oxidative stress
3. **Neuroinflammation**: Microglial activation and pro-inflammatory cytokines
4. **Impaired Proteostasis**: Dysfunction in autophagy-lysosomal and ubiquitin-proteasome systems

## Genetic Risk Factors
- **SNCA**: Encodes alpha-synuclein; duplications/triplications cause familial PD
- **LRRK2**: Most common cause of familial PD; kinase activity inhibitors in development
- **GBA1**: Glucocerebrosidase mutations; strongest genetic risk factor for sporadic PD
- **PINK1/Parkin**: Mitophagy pathway genes; early-onset PD

## Relationships

### Affected Brain Regions
- → [[entities/Organ/Substantia Nigra\|Substantia Nigra]] (organ) - *Primary site of dopaminergic neuron loss*
- → [[entities/Organ/Striatum\|Striatum]] (organ) - *Dopamine depletion target*
- → [[entities/Organ/Locus Coeruleus\|Locus Coeruleus]] (organ) - *Noradrenergic degeneration*
- → [[entities/Organ/Basal Ganglia\|Basal Ganglia]] (organ) - *Motor circuit dysfunction*

### Associated Pathways
- → [[entities/pathway/Nigrostriatal Dopamine Pathway\|Nigrostriatal Dopamine Pathway]] (pathway) - *Primary affected pathway*
- → [[entities/pathway/Mitophagy\|Mitophagy]] (pathway) - *Impaired mitochondrial quality control*
- → [[entities/pathway/Alpha-Synuclein Aggregation\|Alpha-Synuclein Aggregation]] (pathway) - *Core pathological process*

### Biomarkers
- ← [[entities/biomarker/Neurofilament Light Chain\|Neurofilament Light Chain]] (biomarker) - *Marker of neurodegeneration*
- ← [[Alpha-Synuclein CSF\|Alpha-Synuclein CSF]] (biomarker) - *Diagnostic potential*
- ← [[entities/Examination/DAT-SPECT\|DAT-SPECT]] (examination) - *Dopamine transporter imaging*

### Treatments
- ← [[Levodopa\|Levodopa]] (drug) - *Gold standard dopamine replacement*
- ← [[Carbidopa\|Carbidopa]] (drug) - *Peripheral decarboxylase inhibitor*
- ← [[Pramipexole\|Pramipexole]] (drug) - *Dopamine agonist*
- ← [[Rasagiline\|Rasagiline]] (drug) - *MAO-B inhibitor*
- ← [[Deep Brain Stimulation\|Deep Brain Stimulation]] (intervention) - *Surgical treatment*

### Neuroprotective Supplements
- ← [[entities/Supplement/Coenzyme Q10\|Coenzyme Q10]] (supplement) - *Mitochondrial support*
- ← [[entities/drug/Creatine\|Creatine]] (supplement) - *Energy metabolism*
- ← [[entities/Supplement/Omega-3 DHA\|Omega-3 DHA]] (supplement) - *Anti-inflammatory*

## References
1. **Review**: Bloem, B.R., et al. (2021). "Parkinson's disease." *The Lancet*.
2. **Pathology**: Spillantini, M.G., et al. (1997). "Alpha-synuclein in Lewy bodies." *Nature*.
